GARP was reported to mediate TGF-β1 activation and immunosuppression by Tregs in tumor-bearing mice, as blocking antibodies against GARP:TGF-β1 complexes induced regressions of tumors otherwise resistant to anti-PD-1 immunotherapy [40]. Here, LRRC32 is linked to neoplasm.